聚乙二醇干扰素α-2a与替比夫定对慢性乙型肝炎患者肾功能影响的比较

彭梅娟; 王伟; 杨晓飞; 郝春秋; 白雪帆; 贾战生; 连建奇; 张野

doi:10.3969/j.issn.1001-5256.2016.04.014

聚乙二醇干扰素α-2a与替比夫定对慢性乙型肝炎患者肾功能影响的比较

DOI: 10.3969/j.issn.1001-5256.2016.04.014

第四军医大学唐都医院全军感染病诊疗中心

基金项目:

国家“十二五”传染病重大专项(2012ZX10002-007-001-006)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 283
- HTML全文浏览量: 26
- PDF下载量: 89
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Influence of pegylated interferonα- 2a versus telbivudine on renal function in patients with chronic hepatitis B

Center for Infectious Diseases, Tangdu Hospital, Fourth Military Medical University

Research funding:

摘要

摘要:
目的观察聚乙二醇干扰素（PEG-IFN）α-2a与替比夫定（Ld T）治疗对慢性乙型肝炎（CHB）患者肾功能的影响。方法回顾性分析2007年7月-2013年3月于第四军医大学唐都医院进行Ⅳ期临床试验的初治HBe Ag阳性CHB患者临床资料,共纳入患者92例,其中39例皮下注射PEG-IFNα-2a(PEG-IFNα-2a组),180μg/周;53例接受Ld T抗病毒治疗（Ld T组）,600 mg/d。比较基线、治疗24周和48周时患者HBV DNA阴转率、ALT复常率、血清肌酐、尿素氮和估算肾小球滤过率（e GFR）的变化,其中e GFR分别采用慢性肾病流行病学合作研究（CKD-EPI）和简化的肾病饮食改良（MDRD）2种方法进行计算。对于符合正态分布的计量资料2组间比较采用独立样本t检验,不符合正态分布的计量资料2组间比较采用Wilcoxon秩和检验,组内治疗前后比较采用重复测量数据的方差分析,在进行重复测量数据方差分析前对资料进行Mauchly球形检验;计数资料组间比较采用χ2
- 肝炎,乙型,慢性 /
- 肾功能试验 /
- 干扰素α-2a /
- 替比夫定
Abstract:
Objective To investigate the influence of pegylated interferonα- 2a( PEG- IFNα- 2a) versus telbivudine( Ld T) on renal function in patients with chronic hepatitis B( CHB). Methods The clinical data of 92 previously untreated HBe Ag- positive CHB patients who participated in the CHB IV clinical trial in Tangdu Hospital of Fourth Military Medical University from July 2007 to March 2013 were analyzed retrospectively,and among these patients,39 received subcutaneous injection of PEG- IFNα- 2a 180 μg / week( PEG- IFNα- 2a group) and 53 received antiviral therapy with Ld T 600 mg / d( Ld T group). The HBV DNA clearance rate,alanine aminotransferase( ALT)normalization rate,serum creatinine,urea nitrogen,and estimated glomerular filtration rate( e GFR) at baseline and weeks 24 and 48 of treatment were calculated and analyzed,and e GFR was calculated by Chronic Kidney Disease Epidemiology Collaboration( CKD- EPI) or Modification of Diet in Renal Disease( MDRD). The independent samples t- test was used for comparison of normally distributed continuous data between the two groups,and the Wilcoxon rank sum test was used for comparison of continuous data with non- normal distribution between the two groups; the repeated measures analysis of variance was used for comparison of data before and after treatment within one group,and Mauchly's test of sphericity was performed for data before the repeated measures analysis of variance; the chi- square test was used for comparison of categorical data between the two groups. Results In the PEG- IFNα- 2a group,serum creatinine decreased significantly at weeks 24 and 48 of treatment compared with the baseline value( 0. 68 ± 0. 11 mg / dl and 0. 67 ± 0. 11 mg / dl vs 0. 75 ± 0. 11 mg / dl,P<0. 000 1),and e GFR increased significantly at week 24 [128. 30 ± 10. 98 ml / min /1. 73 m2( CKD- EPI) or 143. 90 ± 25. 82 ml/min/1. 73m2( MDRD) ]and week 48 [128. 00 ± 10. 17 ml/min/1. 73 m2( CKD- EPI) or 144. 30 ± 24. 68 ml/min/1. 73 m2( MDRD) ] compared with the baseline value [123. 10 ± 9. 64 ml / min /1. 73 m2( CKD- EPI) or 127. 40 ± 20. 16 ml/min/1. 73 m2( MDRD) ]( P < 0. 000 1). In the Ld T group,serum creatinine( 0. 73 ± 0. 13 mg / dl) and e GFR [122. 30 ± 11. 22 ml / min /1. 73 m2( CKD- EPI) or 128. 10 ± 20. 67 ml/min /1. 73 m2( MDRD) ]at week 24 showed significant differences from those at baseline [serum creatinine: 0. 74 ± 0. 13 mg/dl; e GFR:121. 50 ± 11. 21 ml / min /1. 73 m2( CKD- EPI) or 126. 40 ± 20. 96 ml/min/1. 73 m2( MDRD) ]( P >0. 05); compared with the baseline values,serum creatinine at week 48( 0. 68 ± 0. 12 mg / dl) decreased significantly( P < 0. 000 1),while e GFR [125. 30 ± 11. 55 ml / min /1. 73 m2( CKD- EPI) or 138. 00 ± 25. 94 ml/min/1. 73 m2( MDRD) ]increased significantly( P < 0. 000 1). At week 48 of treatment,the Ld T group had significantly higher HBV DNA clearance rate and ALT normalization rate than the PEG- IFNα- 2a group( HBV DNA seroconversion rate: 60. 4% vs 38. 5%,χ~2= 6. 17,P = 0. 037; ALT normalization rate: 75. 5% vs 33. 3%; χ~2= 16. 34,P < 0. 000 1). Conclusion PEG- IFNα- 2a and Ld T do not influence renal function in CHB patients.
- hepatitis B,chronic /
- kidney function tests /
- interferon alfa-2a /
- telbivudine

HTML全文

参考文献(14)

[1]GANEM D,PRINCE AM.Hepatitis B virus infection-natural history and clinical consequences[J].N Engl J Med,2004,350(11):1118-1129.

[2]COMBES B,SHOREY J,BARRERA A,et al.Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane[J].Lancet,1971,2(7718):234-237.

[3]CAI JJ,HAN T.Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J].J Chin Hepatol,2014,30(12):1352-1356.(in Chinese)蔡均均,韩涛.肝硬化患者急性肾损伤的诊断与治疗[J].临床肝胆病杂志,2014,30(12):1352-1356.

[4]CONJEEVARAM HS,HOOFNAGLE JH,AUSTIN HA,et al.Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa[J].Gastroenterology,1995,109(2):540-546.

[5]FONTANA RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,2009,49(5 Suppl):s185-s195.

[6]GANE EJ,DERAY G,LIAW YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B[J].Gastroenterology,2014,146(1):138-146.

[7]LI W,ZHANG DZ.Influence of monotherapy with telbivudine or entecavir on renal function in patients with chronic hepatitis B[J].Chin JHepatol,2015,23(6):407-411.(in Chinese)李伟,张大志.替比夫定与恩替卡韦治疗慢性乙型肝炎患者对肾脏功能影响的比较[J].中华肝脏病杂志,2015,23(6):407-411.

[8]LEE M,OH S,LEE HJ,et al.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy[J].J Viral Hepat,2014,21(12):873-881.

[9]WANG Y,OU XJ,MA H.The influence of telbivudine on renal function in patients with chronic hepatitis B[J].J Clin Exp Med,2015,14(4):336-339.(in Chinese)王宇,欧晓娟,马红.替比夫定对慢性乙型肝炎患者肾功能的影响[J].临床和实验医学杂志,2015,14(4):336-339.

[10]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[11]LEVEY AS,STEVENS LA,SCHMID CH,et al.A new equation to estimate glomerular filtration rate[J].Ann Intern Med,2009,150(9):604-612.

[12]LEVEY AS,BOSCH JP,LEWIS JB,et al.A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation.Modification of Diet in Renal Disease Study Group[J].Ann Intern Med,1999,130(6):461-470.

[13]MALLET V,SCHWARZINGER M,VALLET-PICHARD A,et al.Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection[J].Clin Gastroenterol Hepatol,2015,13(6):1181-1188.

[14]MEDERACKE I,YURDAYDIN C,GROβHENNIG A,et al.Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection[J].J Viral Hepat,2012,19(6):387-395.

施引文献

资源附件(0)

访问统计